nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—TFE3—vascular cancer	0.0717	0.0717	CbGpPWpGaD
Sirolimus—EIF4E—Signaling mediated by p38-alpha and p38-beta—MITF—vascular cancer	0.0707	0.0707	CbGpPWpGaD
Sirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—WWTR1—vascular cancer	0.0475	0.0475	CbGpPWpGaD
Sirolimus—EIF4E—mTOR signalling—TSC2—vascular cancer	0.0406	0.0406	CbGpPWpGaD
Sirolimus—EIF4E—PKB-mediated events—TSC2—vascular cancer	0.0394	0.0394	CbGpPWpGaD
Sirolimus—FKBP1A—TOR Signaling—TSC2—vascular cancer	0.0236	0.0236	CbGpPWpGaD
Sirolimus—MTOR—RANKL/RANK Signaling Pathway—MITF—vascular cancer	0.0203	0.0203	CbGpPWpGaD
Sirolimus—EIF4E—mTOR signaling pathway—TSC2—vascular cancer	0.0198	0.0198	CbGpPWpGaD
Sirolimus—EIF4E—PI3K Cascade—TSC2—vascular cancer	0.0194	0.0194	CbGpPWpGaD
Sirolimus—FGF2—Neural Crest Differentiation—MITF—vascular cancer	0.0168	0.0168	CbGpPWpGaD
Sirolimus—MTOR—mTOR signalling—TSC2—vascular cancer	0.0167	0.0167	CbGpPWpGaD
Sirolimus—MTOR—FSH signaling pathway—TSC2—vascular cancer	0.0167	0.0167	CbGpPWpGaD
Sirolimus—MTOR—PKB-mediated events—TSC2—vascular cancer	0.0163	0.0163	CbGpPWpGaD
Sirolimus—EIF4E—IRS-mediated signalling—TSC2—vascular cancer	0.0162	0.0162	CbGpPWpGaD
Sirolimus—EIF4E—IRS-related events—TSC2—vascular cancer	0.0158	0.0158	CbGpPWpGaD
Sirolimus—EIF4E—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.0156	0.0156	CbGpPWpGaD
Sirolimus—EIF4E—IGF1R signaling cascade—TSC2—vascular cancer	0.0152	0.0152	CbGpPWpGaD
Sirolimus—EIF4E—Insulin receptor signalling cascade—TSC2—vascular cancer	0.0152	0.0152	CbGpPWpGaD
Sirolimus—MTOR—TOR Signaling—TSC2—vascular cancer	0.0133	0.0133	CbGpPWpGaD
Sirolimus—EIF4E—Signaling by Insulin receptor—TSC2—vascular cancer	0.0126	0.0126	CbGpPWpGaD
Sirolimus—MTOR—LKB1 signaling events—TSC2—vascular cancer	0.0115	0.0115	CbGpPWpGaD
Sirolimus—FGF2—PI3K Cascade—TSC2—vascular cancer	0.0108	0.0108	CbGpPWpGaD
Sirolimus—EIF4E—BDNF signaling pathway—TSC2—vascular cancer	0.0106	0.0106	CbGpPWpGaD
Sirolimus—MTOR—Wnt Signaling Pathway Netpath—TSC2—vascular cancer	0.00991	0.00991	CbGpPWpGaD
Sirolimus—EIF4E—Insulin Signaling—TSC2—vascular cancer	0.00977	0.00977	CbGpPWpGaD
Sirolimus—FGF2—IRS-mediated signalling—TSC2—vascular cancer	0.00901	0.00901	CbGpPWpGaD
Sirolimus—FGF2—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00893	0.00893	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events—TSC2—vascular cancer	0.00876	0.00876	CbGpPWpGaD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.00868	0.00868	CbGpPWpGaD
Sirolimus—FGF2—Insulin receptor signalling cascade—TSC2—vascular cancer	0.00846	0.00846	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—TSC2—vascular cancer	0.00846	0.00846	CbGpPWpGaD
Sirolimus—MTOR—mTOR signaling pathway—TSC2—vascular cancer	0.00819	0.00819	CbGpPWpGaD
Sirolimus—FGF2—PI-3K cascade—TSC2—vascular cancer	0.00804	0.00804	CbGpPWpGaD
Sirolimus—MTOR—PI3K Cascade—TSC2—vascular cancer	0.00799	0.00799	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TSC2—vascular cancer	0.0079	0.0079	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—TSC2—vascular cancer	0.00785	0.00785	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—TSC2—vascular cancer	0.00779	0.00779	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00761	0.00761	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—TSC2—vascular cancer	0.00702	0.00702	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—WWTR1—vascular cancer	0.00693	0.00693	CbGpPWpGaD
Sirolimus—MTOR—IRS-mediated signalling—TSC2—vascular cancer	0.00669	0.00669	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00662	0.00662	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events—TSC2—vascular cancer	0.0065	0.0065	CbGpPWpGaD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.00644	0.00644	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—TSC2—vascular cancer	0.00628	0.00628	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—TSC2—vascular cancer	0.00628	0.00628	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—TSC2—vascular cancer	0.00601	0.00601	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—TSC2—vascular cancer	0.00597	0.00597	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—TSC2—vascular cancer	0.00582	0.00582	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—TSC2—vascular cancer	0.00578	0.00578	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00575	0.00575	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—TSC2—vascular cancer	0.00566	0.00566	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00565	0.00565	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—TSC2—vascular cancer	0.0054	0.0054	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—TSC2—vascular cancer	0.00538	0.00538	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—TSC2—vascular cancer	0.00535	0.00535	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—TSC2—vascular cancer	0.00533	0.00533	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00525	0.00525	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—TSC2—vascular cancer	0.00521	0.00521	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—TSC2—vascular cancer	0.00501	0.00501	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00501	0.00501	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—TSC2—vascular cancer	0.00501	0.00501	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—TSC2—vascular cancer	0.00497	0.00497	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00492	0.00492	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—TSC2—vascular cancer	0.0049	0.0049	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—WWTR1—vascular cancer	0.00472	0.00472	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD34—vascular cancer	0.00471	0.00471	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—TSC2—vascular cancer	0.00464	0.00464	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—WWTR1—vascular cancer	0.00451	0.00451	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—TSC2—vascular cancer	0.00446	0.00446	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00444	0.00444	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—TSC2—vascular cancer	0.00439	0.00439	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD34—vascular cancer	0.00432	0.00432	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.00429	0.00429	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00427	0.00427	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00422	0.00422	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—TSC2—vascular cancer	0.0042	0.0042	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—TSC2—vascular cancer	0.00403	0.00403	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—TSC2—vascular cancer	0.00401	0.00401	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—TSC2—vascular cancer	0.00399	0.00399	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—TSC2—vascular cancer	0.00397	0.00397	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—TSC2—vascular cancer	0.00395	0.00395	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00389	0.00389	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—TSC2—vascular cancer	0.00372	0.00372	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—TSC2—vascular cancer	0.00372	0.00372	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00372	0.00372	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—TSC2—vascular cancer	0.00368	0.00368	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00365	0.00365	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—TSC2—vascular cancer	0.00364	0.00364	CbGpPWpGaD
Sirolimus—FGF2—Disease—WWTR1—vascular cancer	0.00358	0.00358	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—TSC2—vascular cancer	0.00344	0.00344	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—TSC2—vascular cancer	0.00341	0.00341	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—WWTR1—vascular cancer	0.00331	0.00331	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00329	0.00329	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD34—vascular cancer	0.0032	0.0032	CbGpPWpGaD
Sirolimus—MTOR—Disease—WWTR1—vascular cancer	0.00266	0.00266	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD34—vascular cancer	0.00262	0.00262	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—TSC2—vascular cancer	0.00253	0.00253	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—WWTR1—vascular cancer	0.00251	0.00251	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—TSC2—vascular cancer	0.00204	0.00204	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—TSC2—vascular cancer	0.00195	0.00195	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD34—vascular cancer	0.00194	0.00194	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—WWTR1—vascular cancer	0.00191	0.00191	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—TSC2—vascular cancer	0.00187	0.00187	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—WWTR1—vascular cancer	0.00186	0.00186	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—WWTR1—vascular cancer	0.00176	0.00176	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TSC2—vascular cancer	0.00144	0.00144	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—TSC2—vascular cancer	0.00139	0.00139	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TSC2—vascular cancer	0.00138	0.00138	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TSC2—vascular cancer	0.00132	0.00132	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—WWTR1—vascular cancer	0.00127	0.00127	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TSC2—vascular cancer	0.00113	0.00113	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—HBA1—vascular cancer	0.00107	0.00107	CbGpPWpGaD
Sirolimus—FGF2—Disease—TSC2—vascular cancer	0.00105	0.00105	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HBA1—vascular cancer	0.000982	0.000982	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TSC2—vascular cancer	0.000967	0.000967	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—WWTR1—vascular cancer	0.000957	0.000957	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TSC2—vascular cancer	0.000841	0.000841	CbGpPWpGaD
Sirolimus—MTOR—Disease—TSC2—vascular cancer	0.000777	0.000777	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSC2—vascular cancer	0.000733	0.000733	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HBA1—vascular cancer	0.00071	0.00071	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—WWTR1—vascular cancer	0.00059	0.00059	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSC2—vascular cancer	0.000544	0.000544	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HBA1—vascular cancer	0.000536	0.000536	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HBA1—vascular cancer	0.00033	0.00033	CbGpPWpGaD
